A Phase 2 interventional study of Finerenone (BAY94-8862 ) 10 mg and Empagliflozin in Type 2 Diabetes Mellitus and Chronic Kidney Disease, sponsored by Bayer. Completed at 173 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing finerenone in Diabetes Mellitus, Type 2 — 5 open to participants now, 6 under way, none of them phase 3. finerenone · Diabetes Mellitus, Type 2.
Among the 13 studies testing finerenone in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is the only one that started in 2022, is one of 3 in phase 2, and was the 4th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →5 of the 13 studies testing finerenone in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Peter Rossing · Sites in Denmark
Ages 40+
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
University of Aarhus · Sites in Denmark
Ages 18+
Baylor Research Institute · Sites in United States
Ages 18–84
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18+
By country, each count listing its studies:
finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,664 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 13 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 9 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
37 studies in Diabetes Mellitus, Type 2 by Bayer: 3 open now, 6 under way, none of them phase 3. Of 29 finished, 4 (14%) have results posted.
Among the 37 studies in Diabetes Mellitus, Type 2 by Bayer, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2022, is one of 3 in phase 2, and was the 23rd registered.
Bayer’s Diabetes Mellitus, Type 2 studies by the year they started, since 2008.
2 of the studies testing finerenone in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07026539University of AarhusEffect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes. | 2026-12-31 |
| NCT07667517First Affiliated Hospital of Zhejiang UniversityFinerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing finerenone in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 37 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.
Empagliflozin lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine.
In this study, the researchers want to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of the participants' kidney function compared to either treatment alone. For this, the level of protein in the urine will be measured. The investigators also want to know how safe the combination is compared to either treatment alone.
Depending on the treatment group, the participants will either take the combination of finerenone and empagliflozin, or finerenone together with a placebo, or empagliflozin together with a placebo, once a day as tablets by mouth. A placebo looks like a treatment but does not have any medicine in it. Importantly, the participants will also continue to take their other current medicine for CKD and T2D.
The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, participants will visit the study site 7 times.
The study team will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant with a clinical diagnosis of chronic kidney disease (CKD) and the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take Finerenone (10 or 20 mg once daily \[OD\]) and Empagliflozin (10 mg OD) for up to 180 days.
Drug: Finerenone (BAY94-8862 ) 10 mg · Drug: Empagliflozin · Drug: Finerenone (BAY94-8862 ) 20 mg
Participants will take Finerenone (10 or 20 mg OD) and matching placebo to Empagliflozin (OD) for up to 180 days.
Drug: Finerenone (BAY94-8862 ) 10 mg · Drug: Empagliflozin Placebo · Drug: Finerenone (BAY94-8862 ) 20 mg
Participants will take Empagliflozin (10 mg OD) and matching placebo to Finerenone (OD). for up to 180 days.
Drug: Empagliflozin · Drug: Finerenone Placebo
oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: \<60 mL/min/1.73 m2
oral administration, once daily
Matching placebo to empagliflozin oral administration, once daily
oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2
Matching Placebo to Finerenone oral administration once daily
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Empagliflozin Alone
Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 180 relative to baseline, estimated using a mixed model for repeated measures. The treatment effect is expressed as the ratio of LS means for the combination therapy group compared with empagliflozin alone. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a marker of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with chronic kidney disease and type 2 diabetes.
Time frame: Baseline and Day 180
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Finerenone Alone
Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 180 relative to baseline in the combination therapy group compared with finerenone alone, estimated using a mixed model for repeated measures. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a measurement of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with type 2 diabetes.
Time frame: Baseline and Day 180
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 210 Relative to Day 180
Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 210 (30 days after stopping the treatment) relative to Day 180, estimated using a mixed model for repeated measures. A ratio above 1 indicates an increase in UACR at Day 210 compared with Day 180. UACR is a measurement of albuminuria, a predictor of long-term renal and cardiovascular outcomes in participants with type 2 diabetes.
Time frame: Up to 210 days
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at 30 Days After End of Treatment Relative to Baseline
Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) relative to baseline, estimated using a mixed model for repeated measures. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a marker of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with type 2 diabetes.
Time frame: Baseline to Day 210 (30 days after End of Treatment)
Number of Participants by Relative Change in UACR Category at Day 180 (>30%, >40%, >50%)
This outcome summarizes the number of participants whose relative change from baseline in urine albumin-to-creatinine ratio (UACR) at Day 180 met prespecified category thresholds (\>30%, \>40%, or \>50%). Relative change was assessed based on baseline and post-baseline UACR measurements. Percentages were calculated using as denominator the number of participants with both a baseline and at least one post-baseline UACR assessment within the specified timeframe. Participants were classified independently within each category.
Time frame: At Day 180
Change From Baseline in eGFR at 30 Days
Change from baseline to Day 30 in estimated glomerular filtration rate (eGFR) was evaluated for each treatment group. Change was calculated as the value at Day 30 minus the baseline value. Negative values indicate a decrease from baseline and positive values indicate an increase from baseline.
Time frame: At Day 30
Number of Participants With an eGFR Decline Greater Than 30% at 30 Days From Baseline
Time frame: Up to 30 days
Change in eGFR at 180 Days and 210 Days From Day 30
Change in estimated glomerular filtration rate (eGFR) from Day 30 to Day 180 and Day 210 was evaluated for each treatment group. Change was calculated as the value at Day 180 or Day 210 minus the value at Day 30. Positive values indicate an increase from Day 30 and negative values indicate a decrease from Day 30.
Time frame: At Day 180 and Day 210
Number of Participants With AKI Events
AKI is defined as any of the following: * An increase in serum creatinine by greater than or equal to 0.3 mg/dL within 48 hours; or * An increase in serum creatinine by greater than or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or * A urine volume less than 0.5 ml/kg/h for 6 hours Total number of AKI events Up to 180 days
Time frame: Up to 180 days
Total Number of AKI Events
AKI is defined as any of the following: * An increase in serum creatinine by greater than or equal to 0.3 mg/dL within 48 hours; or * An increase in serum creatinine by greater than or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or * A urine volume less than 0.5 ml/kg/h for 6 hours Total number of AKI events Up to 180 days
Time frame: Up to 180 days
Number of Participants With Hyperkalemia Events (Moderate Hyperkalemia [5.5 <K+ ≤6.0 mmol/L], Severe Hyperkalemia [K+ >6.0 mmol/L])
Moderate hyperkalemia was defined as K+ \>5.5 to ≤6.0 mmol/L and severe hyperkalemia was defined as K+ \>6.0 mmol/L).
Time frame: Up to 180 days
Change From Baseline in K+
Serum potassium values (mmol/L) were assessed at baseline and scheduled post-baseline visits. Results are presented as observed mean potassium concentrations at each time point.
Time frame: At baseline, day 14 and day 180
Number of Participants With Symptomatic Hypotension Events
Number of participants who experienced at least one symptomatic hypotension event during the study period
Time frame: Up to 180 days
Total Number of Symptomatic Hypotension Events
Symptomatic hypotension events were assessed at all study visits and were documented as adverse events. The outcome represents the total number of symptomatic hypotension events reported during the study period.
Time frame: Up to 180 days
Number of Participants With Genital Mycotic Events
The outcome represents the number of participants who experienced at least one genital mycotic event during the study period.
Time frame: Up to 180 days
Total Number of Genital Mycotic Events
Occurrence of urinary tract infection events were assessed at all study visits and documented as AEs.
Time frame: Up to 180 days
Number of Participants With Urosepsis and Pyelonephritis Events
Time frame: Up to 180 days
Total Number of Urosepsis and Pyelonephritis Events
Occurrence of urosepsis and pyelonephritis events were assessed at all study visits and documented as AEs.
Time frame: Up to 180 days
Number of Participants With Ketoacidosis Events
Time frame: Up to 180 days
Total Number of Ketoacidosis Events
Occurrence of ketoacidosis events were assessed at all study visits and documented as AEs.
Time frame: Up to 180 days
Number of Participants With Necrotizing Fasciitis of the Perineum Events
Time frame: Up to 180 days
Number of Participants With Severe Hypoglycemia Events
Severe hypoglycemia was defined as glucose level of \<3.0 mmol/L (\<54 mg/dL) is sufficiently low to indicate serious, clinically important hypoglycemia. In addition, severe hypoglycemia, as defined by the ADA denotes severe cognitive impairment requiring external assistance for recovery.
Time frame: Up to 180 days
A total of 1664 participants were screened and signed the informed consent form for the study. 846 participants were screen failures and did not complete screening. The study was conducted at 163 centers in 14 countries/regions across Asia, Europe and North America from 23 Jun 2022 (First Patient First Visit) to 17 Mar 2025 (Last Patient Last Visit).
| Milestone | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Started | 273 | 273 | 272 |
| Treated | 271 | 270 | 271 |
| Included in full analysis set (fas) | 269 | 264 | 267 |
| Included in safety analysis set (saf) | 268 | 264 | 266 |
| Completed | 240 | 232 | 238 |
| Not completed | 33 | 41 | 34 |
| Withdrew: Adverse event | 13 | 11 | 10 |
| Withdrew: Death | 1 | 0 | 2 |
| Withdrew: Physician decision | 5 | 2 | 0 |
| Withdrew: Withdrawal by subject | 5 | 12 | 10 |
| Withdrew: Lost to follow-up | 2 | 3 | 3 |
| Withdrew: Randomized by mistake | 1 | 0 | 2 |
| Withdrew: Other reasons | 1 | 4 | 1 |
| Withdrew: Gcp violation | 3 | 6 | 5 |
| Withdrew: Never took study drug | 2 | 3 | 1 |
Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 180 relative to baseline, estimated using a mixed model for repeated measures. The treatment effect is expressed as the ratio of LS means for the combination therapy group compared with empagliflozin alone. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a marker of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with chronic kidney disease and type 2 diabetes.
| ratio | Finerenone and Empagliflozin | Empagliflozin and Finerenone Placebo |
|---|---|---|
| Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Empagliflozin Alone | 0.483 (0.435 to 0.537) | 0.708 (0.636 to 0.789) |
Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 180 relative to baseline in the combination therapy group compared with finerenone alone, estimated using a mixed model for repeated measures. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a measurement of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with type 2 diabetes.
| Ratio | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo |
|---|---|---|
| Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Finerenone Alone | 0.483 (0.435 to 0.537) | 0.683 (0.613 to 0.761) |
Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 210 (30 days after stopping the treatment) relative to Day 180, estimated using a mixed model for repeated measures. A ratio above 1 indicates an increase in UACR at Day 210 compared with Day 180. UACR is a measurement of albuminuria, a predictor of long-term renal and cardiovascular outcomes in participants with type 2 diabetes.
| ratio | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 210 Relative to Day 180 | 1.631 (1.493 to 1.782) | 1.448 (1.323 to 1.585) | 1.442 (1.318 to 1.577) |
Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) relative to baseline, estimated using a mixed model for repeated measures. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a marker of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with type 2 diabetes.
| ratio | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at 30 Days After End of Treatment Relative to Baseline | 0.818 (0.734 to 0.911) | 0.853 (0.762 to 0.956) | 0.895 (0.801 to 1.000) |
This outcome summarizes the number of participants whose relative change from baseline in urine albumin-to-creatinine ratio (UACR) at Day 180 met prespecified category thresholds (\>30%, \>40%, or \>50%). Relative change was assessed based on baseline and post-baseline UACR measurements. Percentages were calculated using as denominator the number of participants with both a baseline and at least one post-baseline UACR assessment within the specified timeframe. Participants were classified independently within each category.
| Participants | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Participants with relative change from baseline in UACR >30% at Day 180 | 168 | 123 | 123 |
| Participants with relative change from baseline in UACR >40% at Day 180 | 154 | 104 | 103 |
| Participants with relative change from baseline in UACR >50% at Day 180 | 131 | 84 | 76 |
Change from baseline to Day 30 in estimated glomerular filtration rate (eGFR) was evaluated for each treatment group. Change was calculated as the value at Day 30 minus the baseline value. Negative values indicate a decrease from baseline and positive values indicate an increase from baseline.
| mL/min/1.73 m^2 | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Change From Baseline in eGFR at 30 Days | -5.593 (-6.669 to -4.517) | -2.036 (-3.131 to -0.941) | -3.788 (-4.878 to -2.698) |
| Participants | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Number of Participants With an eGFR Decline Greater Than 30% at 30 Days From Baseline | 17 | 10 | 3 |
Change in estimated glomerular filtration rate (eGFR) from Day 30 to Day 180 and Day 210 was evaluated for each treatment group. Change was calculated as the value at Day 180 or Day 210 minus the value at Day 30. Positive values indicate an increase from Day 30 and negative values indicate a decrease from Day 30.
| mL/min/1.73 m^2 | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Day 180 | 0.874 (-0.266 to 2.015) | -0.285 (-1.487 to 0.917) | 1.255 (0.107 to 2.402) |
| Day 210 | 5.120 (3.993 to 6.247) | 0.953 (-0.264 to 2.170) | 3.976 (2.826 to 5.126) |
AKI is defined as any of the following: * An increase in serum creatinine by greater than or equal to 0.3 mg/dL within 48 hours; or * An increase in serum creatinine by greater than or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or * A urine volume less than 0.5 ml/kg/h for 6 hours Total number of AKI events Up to 180 days
| Participants | Finerenone and Empagliflozin | Finerenone and Emagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Number of Participants With AKI Events | 5 | 3 | 0 |
AKI is defined as any of the following: * An increase in serum creatinine by greater than or equal to 0.3 mg/dL within 48 hours; or * An increase in serum creatinine by greater than or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or * A urine volume less than 0.5 ml/kg/h for 6 hours Total number of AKI events Up to 180 days
| events | Finerenone and Empagliflozin | Finerenone and Emagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Total Number of AKI Events | 5 | 3 | 0 |
Moderate hyperkalemia was defined as K+ \>5.5 to ≤6.0 mmol/L and severe hyperkalemia was defined as K+ \>6.0 mmol/L).
| Participants | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Moderate Hyperkalemia Events (K+ >5.5 mmol/L to ≤6.0 mmol/L) | 33 | 40 | 20 |
| Severe Hyperkalemia Events (K+ >6.0 mmol/L) | 12 | 12 | 7 |
Serum potassium values (mmol/L) were assessed at baseline and scheduled post-baseline visits. Results are presented as observed mean potassium concentrations at each time point.
| mmol/L | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Baseline | 4.42 ± 0.39 | 4.51 ± 0.46 | 4.52 ± 0.41 |
| Day 14 | 4.68 ± 0.48 | 4.70 ± 0.51 | 4.53 ± 0.41 |
| Day 180 | 4.67 ± 0.51 | 4.68 ± 0.54 | 4.55 ± 0.48 |
Number of participants who experienced at least one symptomatic hypotension event during the study period
| Participants | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Number of Participants With Symptomatic Hypotension Events | 3 | 0 | 0 |
Symptomatic hypotension events were assessed at all study visits and were documented as adverse events. The outcome represents the total number of symptomatic hypotension events reported during the study period.
| events | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Total Number of Symptomatic Hypotension Events | 3 | 0 | 0 |
The outcome represents the number of participants who experienced at least one genital mycotic event during the study period.
| Participants | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Number of Participants With Genital Mycotic Events | 4 | 0 | 4 |
Occurrence of urinary tract infection events were assessed at all study visits and documented as AEs.
| events | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Total Number of Genital Mycotic Events | 4 | 0 | 6 |
| Participants | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Number of Participants With Urosepsis and Pyelonephritis Events | 1 | 0 | 1 |
Occurrence of urosepsis and pyelonephritis events were assessed at all study visits and documented as AEs.
| events | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Total Number of Urosepsis and Pyelonephritis Events | 2 | 0 | 1 |
| Participants | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Number of Participants With Ketoacidosis Events | 0 | 0 | 0 |
Occurrence of ketoacidosis events were assessed at all study visits and documented as AEs.
| events | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Total Number of Ketoacidosis Events | 0 | 0 | 0 |
| Participants | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Number of Participants With Necrotizing Fasciitis of the Perineum Events | 0 | 0 | 0 |
Severe hypoglycemia was defined as glucose level of \<3.0 mmol/L (\<54 mg/dL) is sufficiently low to indicate serious, clinically important hypoglycemia. In addition, severe hypoglycemia, as defined by the ADA denotes severe cognitive impairment requiring external assistance for recovery.
| Participants | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo |
|---|---|---|---|
| Number of Participants With Severe Hypoglycemia Events | 0 | 0 | 0 |
Collected over All-cause mortality was assessed from the randomization through the end of follow-up (up to 210 days). Serious and other adverse events were assessed from the first dose through the end of follow-up, including the treatment period (approximately 180 days) and the post-treatment follow-up period up to 30 days after the last dose (Day 210).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Finerenone + Empagliflozin Group | 3/268 (1.1%) | 19/268 (7.1%) | 141/268 (52.6%) |
| Finerenone Group | 0/264 (0%) | 16/264 (6.1%) | 136/264 (51.5%) |
| Empagliflozin Group | 3/266 (1.1%) | 17/266 (6.4%) | 129/266 (48.5%) |
| Never Received Treatment | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | Finerenone + Empagliflozin Group | Finerenone Group | Empagliflozin Group | Never Received Treatment |
|---|---|---|---|---|
| CellulitisInfections and infestations | 1/268 | 3/264 | 1/266 | 0/2 |
| Acute kidney injuryRenal and urinary disorders | 0/268 | 2/264 | 0/266 | 0/2 |
| PneumoniaInfections and infestations | 0/268 | 1/264 | 2/266 | 0/2 |
| Chest painGeneral disorders and administration site conditions | 2/268 | 1/264 | 0/266 | 0/2 |
| Retinal artery occlusionEye disorders | 0/268 | 1/264 | 0/266 | 0/2 |
| Appendicitis perforatedInfections and infestations | 0/268 | 1/264 | 0/266 | 0/2 |
| Pneumonia aspirationInfections and infestations | 0/268 | 1/264 | 0/266 | 0/2 |
| Urinary tract infectionInfections and infestations | 1/268 | 1/264 | 0/266 | 0/2 |
| Campylobacter colitisInfections and infestations | 0/268 | 1/264 | 0/266 | 0/2 |
| COVID-19Infections and infestations | 0/268 | 1/264 | 0/266 | 0/2 |
| Event | Finerenone + Empagliflozin Group | Finerenone Group | Empagliflozin Group | Never Received Treatment |
|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 25/268 | 27/264 | 10/266 | 0/2 |
| Glomerular filtration rate decreasedInvestigations | 17/268 | 11/264 | 10/266 | 0/2 |
| NasopharyngitisInfections and infestations | 3/268 | 7/264 | 11/266 | 0/2 |
| DiarrhoeaGastrointestinal disorders | 9/268 | 9/264 | 6/266 | 0/2 |
| DizzinessNervous system disorders | 9/268 | 8/264 | 2/266 | 0/2 |
| Urinary tract infectionInfections and infestations | 6/268 | 2/264 | 8/266 | 0/2 |
| FatigueGeneral disorders and administration site conditions | 3/268 | 7/264 | 2/266 | 0/2 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/268 | 7/264 | 2/266 | 0/2 |
| HypertensionVascular disorders | 1/268 | 3/264 | 7/266 | 0/2 |
| Blood creatinine increasedInvestigations | 7/268 | 1/264 | 0/266 | 0/2 |
| Age, Continuous(years) | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo | Total |
|---|---|---|---|---|
| Mean | 67.7 ± 10.0 | 65.5 ± 10.7 | 66.2 ± 10.1 | 66.5 ± 10.3 |
| Sex: Female, Male(Participants) | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo | Total |
|---|---|---|---|---|
| Female | 67 | 61 | 70 | 198 |
| Male | 202 | 203 | 197 | 602 |
| Ethnicity (NIH/OMB)(Participants) | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 28 | 26 | 29 | 83 |
| Not Hispanic or Latino | 239 | 235 | 238 | 712 |
| Unknown or Not Reported | 2 | 3 | 0 | 5 |
| Race (NIH/OMB)(Participants) | Finerenone and Empagliflozin | Finerenone and Empagliflozin Placebo | Empagliflozin and Finerenone Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 1 | 4 |
| Asian | 114 | 132 | 125 | 371 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 22 | 21 | 24 | 67 |
| White | 130 | 105 | 116 | 351 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 4 | 1 | 6 |
Showing the first 100 of 173 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Jun 2022 to primary completion in Mar 2025, 32 months.
Results were first posted in Jul 2026, 1 year 3 months after primary completion.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 32 months is above that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Finerenone · Empagliflozin